Dashboard
Poor long term growth as Net Sales has grown by an annual rate of 4.71% and Operating profit at 9.64%
The company has declared Positive results for the last 10 consecutive quarters
With ROE of 13.43%, it has a expensive valuation with a 3.66 Price to Book Value
High Institutional Holdings at 92.38%
Stock DNA
Capital Markets
USD 94,629 Million (Large Cap)
27.00
NA
309.36%
-999,999.00
13.59%
3.41
Total Returns (Price + Dividend) 
CME Group, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
Is CME Group, Inc. technically bullish or bearish?
As of 12 August 2025, the technical trend for CME Group, Inc. has changed from bullish to mildly bullish. The weekly MACD and KST are both mildly bearish, while the monthly MACD and KST are bullish. The daily moving averages indicate a mildly bullish stance. Bollinger Bands show a bearish signal on the weekly chart but a mildly bullish signal on the monthly chart. Dow Theory is mildly bearish on both weekly and monthly time frames. In terms of performance, CME Group has underperformed the S&P 500 over the past week and month, with returns of -0.68% and -3.63% compared to 1.05% and 2.33% for the index, respectively. However, it has outperformed the S&P 500 on a year-to-date and one-year basis, with returns of 12.21% and 20.48% versus 12.22% and 17.14%. Over three and five years, CME Group has significantly lagged behind the S&P 500, with returns of 36.04% and 54.15% compared to 70.41% and 96.61%. Overall, ...
Read MoreIs CME Group, Inc. overvalued or undervalued?
As of 30 June 2025, the valuation grade for CME Group, Inc. has moved from attractive to fair, indicating a shift in its perceived value. Based on the current metrics, the company appears to be fairly valued. Key ratios include a P/E ratio of 27, an EV to EBITDA of 22.04, and a Price to Book Value of 3.66. In comparison to peers, CME Group's P/E ratio is higher than The Charles Schwab Corp. at 25.67 and lower than The Goldman Sachs Group, Inc. at 41.63, suggesting a competitive position within the industry. In terms of recent performance, CME Group's stock has returned 20.48% over the past year, slightly outperforming the S&P 500's return of 17.14%. However, over longer periods, such as the 3-year and 5-year returns, CME Group has lagged significantly behind the S&P 500, which returned 70.41% and 96.61%, respectively. This discrepancy may indicate that while the company is currently fairly valued, it faces...
Read More Announcements 
Corporate Actions 
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Mar 2025
Shareholding Compare (%holding) 
Domestic Funds
Held in 210 Schemes (32.99%)
Held by 528 Foreign Institutions (27.29%)
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
YoY Growth in quarter ended Jun 2025 is 10.41% vs 12.67% in Jun 2024
YoY Growth in quarter ended Jun 2025 is 16.01% vs 13.52% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
YoY Growth in year ended Dec 2024 is 9.88% vs 11.15% in Dec 2023
YoY Growth in year ended Dec 2024 is 9.27% vs 19.80% in Dec 2023






